Evaluation of Epidemiological Risk Features and Hematological Parameters in the Lymphoma Patients in the Larkana Region
Article Sidebar
Main Article Content
Abstract
Background: Hodgkin lymphoma (HL) is a type of lymphatic cancer that is distinctly characterized and classified into various subtypes, with varying prognoses based on the stage at diagnosis and treatment modalities. Despite advances in treatment, the specific demographic and clinical factors influencing treatment outcomes and the incidence of side effects, such as chemotherapy-induced anemia and neutropenia, remain under-explored, particularly in diverse regional settings.
Objective: This study aims to evaluate the epidemiological risk features and hematological parameters of lymphoma patients in the Larkana region, with a focus on the impact of chemotherapy on these parameters.
Methods: A case-control study was conducted over twelve months at Linar Hospital in Larkana, involving 40 participants aged between 10 and 70 years. Informed consent was obtained, aligning with ethical standards akin to the Declaration of Helsinki. Two types of blood samples were collected pre- and post-chemotherapy for hematological analysis including total leukocyte count, hemoglobin, and platelet levels, which were assessed using Complete Blood Count (CBC) containers with EDTA. Statistical analysis was performed using Microsoft Excel 2010 and SPSS Version 23, utilizing descriptive statistics and the Student's t-test.
Results: The study documented a decrease in mean hemoglobin levels from 11.42 ± 1.74 g/dL before chemotherapy to 10.65 ± 1.55 g/dL after (p = 0.001), mean white blood cell count from 7.30 ± 2.6 × 10^3/uL to 5.71 ± 2.1 × 10^3/uL (p = 0.003), and platelet count from 297.52 ± 116.2 × 10^3/uL to 230.2 ± 72.6 × 10^3/uL (p = 0.001). These findings indicate a significant hematological impact associated with chemotherapy.
Conclusion: The significant reduction in critical hematological parameters among lymphoma patients’ post-chemotherapy highlights the need for rigorous monitoring and tailored management strategies to mitigate treatment side effects. The findings emphasize the importance of comprehensive patient care and support in improving treatment outcomes in lymphoma.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Schnitzer B. Hodgkin Lymphoma. Hematol Oncol Clin North Am. 2009;23(4):747-68.
Burke J. Hodgkin's Disease: Histopathology and Differential Diagnosis. In: Knowles D, editor. Neoplastic Hematopathology. Baltimore, MD: Williams and Wilkins; 1992. p. 497-533.
American Cancer Society. Cancer Facts & Figures 2010. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf.
Devita VT Jr, Serpick AA, Carbone PP. Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease. Ann Intern Med. 1970;73(6):881-95.
Brenner H, Gondos A, Pulte D. Ongoing Improvement in Long-Term Survival of Patients with Hodgkin Disease at All Ages and Recent Catch-Up of Older Patients. Blood. 2008;111(6):2977-83.
Glaser SL, Hsu JL. Hodgkin's Disease in Asians: Incidence Patterns and Risk Factors in Population-Based Data. Leuk Res. 2002;26(3):261-69.
Maggioncalda A, Malik N, Shenoy P, Smith M, Sinha R, Flowers CR. Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma. Adv Hematol. 2011;2011:736261.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. Guide: Comprendre Les Lymphomes Hodgkiniens. INCa. 2016.
Defossez G, Le Guyader-Peyrou S, Uhry Z, Grosclaude P, Colonna M, Dantony E, Monnereau A. The Lancet. 2012 Sep 1;380:848-57.
Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin Lymphoma. The Lancet. 2012;380(September 1):848-57.
Szakács J, Tilincă M, Mărusteri M, Nicolaescu I. Human Biology. 12th ed. New York, NY: McGraw-Hill Companies; 2010.
Zelenetz AD, Abramson JS, Advani RH, et al. Non-Hodgkin’s Lymphomas. J Natl Compr Canc Netw. 2011;9:484-560.
Bolukbas F, Kutluturkan S. Symptoms and Symptom Clusters in Non-Hodgkin’s Lymphoma Patients in Turkey. Asian Pac J Cancer Prev. 2014;15:7153-8.
Ng AK, LaCasce A, Travis LB. Long-Term Complications of Lymphoma and Its Treatment. J Clin Oncol. 2011;29:1885-92.
Armstrong TS. Symptoms Experience: A Concept Analysis. Oncol Nurs Forum. 2003;30:601-6. doi: 10.1188/03.ONF.601-606
Bröckelmann PJ, Sasse S, Engert A. Balancing Risk and Benefit in Early Stage Classical Hodgkin Lymphoma. Blood. 2018;131:1666-78.
Kaseb H, Babiker HM. Cancer, Hodgkin Lymphoma. StatPearls. StatPearls Publishing; 2019.
Han ZT, Tong YK, He LM, Zhang Y, Sun JZ, Wang TY, Zhang H, Cui YL, Newmark HL, Conney AH, Chang RL. Chemotherapy-Induced Neutropenia: Important New Data to Guide Nursing Assessment and Management. Cancer Ther Support Care. 2006;4(2):21-25.
Friense CR. Chemotherapy-Induced Neutropenia: Important New Data to Guide Nursing Assessment and Management. Cancer Therapy And Supportive Care. 2006;4(2):21-25.
Al-Araji SM, Hamad NJ. Hematological Changes Associated with the Carcinoma of the Uterine Cervix. UOBabylon Journal-Medical Science. 2005;4(1):615-16.